ArticleCell2023
Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy.
Open access · hybridAbstract read
In one paragraph
Article in Cell, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 94 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
94citing papers in PubMed, 3 pooled it
27.6field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
94 citing papers in PubMed, 3 syntheses or guidelines pooled it, 120 citations in OpenAlex.
- Baseline D-dimer as a predictor of immune checkpoint inhibitor efficacy in cancer.Annals of medicine · 2026Pooled it
- The predictive value of the neutrophil/eosinophil ratio in cancer patients undergoing immune checkpoint inhibition: a meta-analysis and a validation cohort in hepatocellular carcinoma.Frontiers in immunology · 2025Pooled it
- Pan-immune inflammation value as a prognostic biomarker for cancer patients treated with immune checkpoint inhibitors.Frontiers in immunology · 2024Pooled it
- Tumor immune dynamics and long-term clinical outcome of stage IIIA NSCLC patients treated with neoadjuvant chemoimmunotherapy.Nature communications · 2025Trial
- T cell immunomonitoring: a comparative analysis of traditional and novel methods to quantify and characterize human antigen-specific T cells.Nature protocols · 2026Review
- Lymph node contraction links sex-biased naive CD8Nature aging · 2026Article
- A p53Molecular therapy. Oncology · 2026Article
- MHCXGraph: a graph-based approach to detecting T-cell receptor cross-reactivity.Briefings in bioinformatics · 2026Article
- Cancer Vaccine Development: Toward Artificial Intelligence-Assisted Personalized Cell Membrane Nanovaccine.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Take Five: harmonization in personalized cancer vaccines for cancer immunotherapy.Experimental & molecular medicine · 2026Review
- Ensembles ofbioRxiv : the preprint server for biology · 2026Article
- The challenge and promise of studying human antigen-specific T cells.Nature reviews. Immunology · 2026Review
- Advances in delivery technologies-powered cancer vaccines.Bioactive materials · 2026Review
- Multi-antigen-targeting T cells in pediatric central nervous system tumors: a phase 1 trial.Nature medicine · 2026Article
- Breathing new life into T-cell receptor-engineered T-cell therapy in solid tumors: enhancing strategies to expand the universality of precision therapy.Experimental hematology & oncology · 2026Review
- Clinical predictors of leptomeningeal metastasis from lung adenocarcinoma based on retrospective analysis.Oncology letters · 2026Article
- TCRBinder: Unified pre-trained language model with paired-chain synergy for predicting T-cell receptor binding specificity.PLoS computational biology · 2026Article
- PMGen: from peptide-MHC structure prediction to peptide generation.Bioinformatics (Oxford, England) · 2026Article
- Identification and prioritisation of tumour antigen candidates from 79 glioblastoma transcriptomes.Cancer immunology, immunotherapy : CII · 2026Article
- Astragaloside IV inhibits nasopharyngeal carcinoma progression by inhibiting SATB2/Wnt/PD-L1 pathway and enhancing the killing activity of T cells.European journal of histochemistry : EJH · 2026Article
34 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
Authors and funding
33 authors at 4 institutions in 2 countries.
Garry DoltonDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Cristina RiusDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Aaron WallDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Barbara SzomolaySystems Immunology Research Institute, Cardiff, Wales CF14 4XN, UK.
Valentina BianchiDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Sarah A E GallowayDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Md Samiul HasanDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Théo MorinDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Marine E CaillaudDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Hannah L ThomasDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Sarah TheakerDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Li Rong TanDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Anna FullerDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Katie TopleyDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Mateusz LegutDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Meriem AttafDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Jade R HopkinsDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Enas BehiryDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Joanna ZabkiewiczDivision of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Caroline AlvaresDivision of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Angharad LloydDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Amber RogersDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Peter HenleyDivision of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Christopher FeganDivision of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Oliver OttmannDivision of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Stephen ManDivision of Cancer and Genetics, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Michael D CrowtherDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK; National Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
Marco DoniaNational Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
Inge Marie SvaneNational Center for Cancer Immune Therapy, Department of Oncology, Copenhagen University Hospital, Herlev, Denmark.
David K ColeDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Paul E BrownThe Zeeman Institute, University of Warwick, Coventry CV4 7AL, UK.
Pierre RizkallahDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK.
Andrew K SewellDivision of Infection and Immunity, Cardiff University School of Medicine, Cardiff, Wales CF14 4XN, UK; Systems Immunology Research Institute, Cardiff, Wales CF14 4XN, UK. Electronic address: sewellak@cardiff.ac.uk.
Cardiff University · GBCopenhagen University Hospital · DKUniversity Hospital of Wales · GBUniversity of Warwick · GB
Funding
Biotechnology and Biological Sciences Research Council BB/H001085/1HCRW_ HRG-16-1318HCRW_ HRG-20-1724(P)Wellcome Trust 220295/Z/20/Z
Abstract
The T cells of the immune system can target tumors and clear solid cancers following tumor-infiltrating lymphocyte (TIL) therapy. We used combinatorial peptide libraries and a proteomic database to reveal the antigen specificities of persistent cancer-specific T cell receptors (TCRs) following successful TIL therapy for stage IV malignant melanoma. Remarkably, individual TCRs could target multiple different tumor types via the HLA A
Indexed as
Antigens, NeoplasmNeoplasmsProteomicsReceptors, Antigen, T-CellEpitopesImmunotherapyLymphocytes, Tumor-InfiltratingAntigens, NeoplasmEpitopesReceptors, Antigen, T-Cellcancer immunotherapyHLA class Ipeptide-HLAT cell receptorTCRTCR-TTILsTIL therapytumor-infiltrating lymphocytes
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.